Nuage Therapeutics develops selective small molecule modulators targeting intrinsically disordered proteins using proprietary assays and chemical biology techniques. The company focuses on treating castration-resistant prostate cancer and other diseases associated with undruggable proteins, addressing significant unmet medical needs in the pharmaceutical landscape.
Funding
$18.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many proteins implicated in cancer and other diseases are intrinsically disordered, lacking a stable three-dimensional structure, which makes them difficult to target with traditional drug discovery methods. This "undruggability" limits therapeutic options for diseases driven by these proteins.
Solution
Nuage Therapeutics is developing selective small molecule modulators that target intrinsically disordered proteins (IDPs). The company employs proprietary assays and chemical biology techniques to identify compounds that can bind to and modulate the function of these challenging targets. By focusing on IDPs, Nuage aims to address unmet medical needs in areas such as castration-resistant prostate cancer and other diseases where these proteins play a critical role. Their approach leverages the principles of biomolecular condensation to discover drugs that can selectively interact with disordered regions of proteins.
Target Audience
The primary target audience includes patients with castration-resistant prostate cancer and other diseases associated with intrinsically disordered proteins, as well as pharmaceutical companies seeking novel drug targets and therapeutic approaches.
Features
- Focus on small molecule modulators of intrinsically disordered proteins (IDPs)
- Proprietary assays for identifying compounds that bind to IDPs
- Chemical biology techniques to modulate IDP function
- Targeting diseases with "undruggable" protein targets
- Development of drugs that selectively interact with disordered regions of proteins